IN2015MN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2015MN00139A IN2015MN00139A IN139MUN2015A IN2015MN00139A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A IN 139MUN2015 A IN139MUN2015 A IN 139MUN2015A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A
- Authority
- IN
- India
- Prior art keywords
- protein
- fragments
- present
- hetero dimeric
- immunoglobulinvariants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261705278P | 2012-09-25 | 2012-09-25 | |
PCT/EP2013/069989 WO2014049003A1 (fr) | 2012-09-25 | 2013-09-25 | Purification d'immunoglobulines hétérodimères |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015MN00139A true IN2015MN00139A (fr) | 2015-10-16 |
Family
ID=49237223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN139MUN2015 IN2015MN00139A (fr) | 2012-09-25 | 2013-09-25 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20150239991A1 (fr) |
EP (2) | EP3401337A1 (fr) |
JP (5) | JP2015529236A (fr) |
KR (1) | KR20150076172A (fr) |
CN (1) | CN104968685A (fr) |
AU (2) | AU2013322710A1 (fr) |
CA (2) | CA3061557A1 (fr) |
HK (1) | HK1215950A1 (fr) |
IL (2) | IL237872B (fr) |
IN (1) | IN2015MN00139A (fr) |
WO (1) | WO2014049003A1 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
CA2824824A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Proteines monovalentes de liaison a l'antigene |
CN103502271B (zh) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗原结合蛋白 |
IN2015MN00139A (fr) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
WO2014177460A1 (fr) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Anticorps modifiés se liant au fcrn humain et procédés d'utilisation |
WO2015033223A2 (fr) * | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
BR112016009919A2 (pt) | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
EP3842455A1 (fr) | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Variants de zone fc avec protéine de ligand a améliorée |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
WO2017074878A1 (fr) | 2015-10-25 | 2017-05-04 | Sanofi | Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih |
GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
RS64771B1 (sr) | 2016-04-13 | 2023-11-30 | Sanofi Sa | Trispecifični i/ili trovalentni vezujući proteini |
BR112018069890A2 (pt) * | 2016-05-02 | 2019-02-05 | Hoffmann La Roche | polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão |
IL265605B1 (en) * | 2016-09-29 | 2024-02-01 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation |
US11319378B2 (en) | 2016-11-18 | 2022-05-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
PT3443006T (pt) * | 2017-03-17 | 2023-10-26 | Sanofi Sa | Proteínas de ligação triespecíficas e/ou trivalentes |
MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
WO2019153200A1 (fr) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation |
CN111902720A (zh) | 2018-03-21 | 2020-11-06 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
EP3773913A1 (fr) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Produits de recombinaison de polypeptides plurispécifiques comprenant une fixation à cd3 contrainte et méthodes d'utilisation associées |
FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
CN112513074A (zh) | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
JP2022504822A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
EP3864044A1 (fr) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Anticorps b7h3 à domaine unique et compositions thérapeutiques associées |
JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス, インコーポレイテッド | Pd-1単一ドメイン抗体およびその治療用組成物 |
SG11202106393SA (en) | 2018-12-24 | 2021-07-29 | Sanofi Sa | Pseudofab-based multispecific binding proteins |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
EP4141025A4 (fr) * | 2019-12-26 | 2024-04-24 | Abl Bio Inc | Procédé de purification d'un peptide biologiquement actif au moyen d'une chromatographie d'affinité à la protéine a |
MX2022009306A (es) | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. |
EP4355786A1 (fr) | 2021-06-16 | 2024-04-24 | Alector LLC | Anticorps anti-mertk et anti-pdl1 bispécifiques et leurs méthodes d'utilisation |
WO2022266221A1 (fr) | 2021-06-16 | 2022-12-22 | Alector Llc | Anticorps anti-mertk monovalents et leurs méthodes d'utilisation |
WO2023240109A1 (fr) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Molécules multispécifiques pour moduler l'activité des lymphocytes t, et leurs utilisations |
WO2024026471A1 (fr) | 2022-07-29 | 2024-02-01 | Alector Llc | Domaines de liaison à l'antigène cd98hc et leurs utilisations |
TW202405020A (zh) | 2022-07-29 | 2024-02-01 | 美商阿列克特有限責任公司 | 轉鐵蛋白受體抗原結合域及其用途 |
WO2024050493A2 (fr) * | 2022-09-02 | 2024-03-07 | Zoetis Services Llc | Mutants d'anticorps équins |
WO2024102948A1 (fr) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Molécules de liaison spécifiques de l'homologue 5 du récepteur fc (fcrh5) et anticorps bispécifiques d'activation des lymphocytes t les comprenant et procédés associés |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
WO1992000373A1 (fr) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Production de melanines a l'aide de microorganismes transformes |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
AU2006259298B2 (en) * | 2005-06-17 | 2012-06-14 | Wyeth Llc | Methods of purifying Fc region containing proteins |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
EP2647388A1 (fr) | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Anticorps dirigés contre l'ERBB3 et leurs utilisations |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
PL2356153T3 (pl) * | 2008-10-01 | 2016-11-30 | Swoiste międzygatunkowo dwuswoiste przeciwciało jednołańcuchowe PSMAXCD3 | |
CA2746330C (fr) | 2008-12-23 | 2017-08-29 | Genentech, Inc. | Variantes d'immunoglobuline de proprietes de liaison vis-a-vis de la proteine a alterees |
CA2753158A1 (fr) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Anticorps humanises qui se fixent au cd19 et leurs utilisations |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
CA2785414C (fr) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Procede de modification de polypeptide pour purifier un multimere de polypeptide |
WO2011131746A2 (fr) * | 2010-04-20 | 2011-10-27 | Genmab A/S | Protéines contenant des anticorps fc hétérodimères et leurs procédés de production |
CA2812739A1 (fr) | 2011-03-25 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Immunoglobulines hetero-dimeriques |
US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
SI2771364T1 (sl) * | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
EP2823422A1 (fr) | 2012-03-06 | 2015-01-14 | FOSS Analytical AB | Procédé, logiciel et interface utilisateur graphique permettant de générer un modèle de prédiction pour une analyse chimiométrique |
ES2728301T3 (es) | 2012-03-13 | 2019-10-23 | Novimmune Sa | Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa |
IN2015MN00139A (fr) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
BR112016009919A2 (pt) * | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
-
2013
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 CA CA3061557A patent/CA3061557A1/fr active Pending
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/fr not_active Withdrawn
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 CA CA2886036A patent/CA2886036A1/fr not_active Abandoned
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Application Discontinuation
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/fr not_active Ceased
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/fr active Application Filing
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2016
- 2016-04-05 HK HK16103843.5A patent/HK1215950A1/zh unknown
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja active Active
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja active Pending
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2900696A1 (fr) | 2015-08-05 |
IL269207A (en) | 2019-11-28 |
CA3061557A1 (fr) | 2014-04-03 |
CN104968685A (zh) | 2015-10-07 |
IL237872B (en) | 2019-09-26 |
AU2013322710A2 (en) | 2015-05-07 |
US20150239991A1 (en) | 2015-08-27 |
AU2018204314A1 (en) | 2018-07-05 |
IL237872A0 (en) | 2015-05-31 |
CA2886036A1 (fr) | 2014-04-03 |
JP2018104444A (ja) | 2018-07-05 |
JP6856610B2 (ja) | 2021-04-07 |
AU2018204314B2 (en) | 2020-05-14 |
JP2015529236A (ja) | 2015-10-05 |
EP3401337A1 (fr) | 2018-11-14 |
WO2014049003A1 (fr) | 2014-04-03 |
US20200010568A1 (en) | 2020-01-09 |
JP2020105203A (ja) | 2020-07-09 |
HK1215950A1 (zh) | 2016-09-30 |
JP2022116326A (ja) | 2022-08-09 |
AU2013322710A1 (en) | 2015-04-16 |
IL269207B (en) | 2022-02-01 |
JP2019073512A (ja) | 2019-05-16 |
KR20150076172A (ko) | 2015-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015MN00139A (fr) | ||
WO2013138793A3 (fr) | Réactifs d'affinité pour la purification de protéines | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
HK1211297A1 (en) | Binding proteins comprising at least two repeat domains against her2 her2 | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
IL254652A0 (en) | Unnatural albumin binding sites | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
MX2019000046A (es) | Anticuerpos anti-il-23. | |
TN2015000124A1 (en) | Compositions and methods for antibodies targeting epo | |
HK1208236A1 (en) | Antigen binding proteins that bind ccr2 ccr2 | |
EP2883882A4 (fr) | Procédé de purification des protéines | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
HK1198832A1 (en) | Fn14 binding proteins and uses thereof fn14 | |
ME02162B (me) | Proces prečišćavanja proteina | |
IL229722A0 (en) | Dimeric binding proteins based on modified ubiquitin | |
EP3067367A4 (fr) | Procédé de purification de protéine recombinée | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
WO2013093627A3 (fr) | Maturation d'affinité in silico | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
TN2013000186A1 (en) | Anti-il-23 antibodies |